Recombinant Antibodies for Histone PTM Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies to histone post-translational modifications (PTMs) are often polyclonal and lack reproducibility, hindering reliable and consistent data acquisition in chromatin biology and molecular epigenetics research.
Innovation Solution
Development of recombinant antibodies with specific complementarity determining regions (CDRs) that selectively and with high affinity bind to particular histone PTMs, such as H3K9me3, H3K36me3, and H4K20me3, overcoming the limitations of existing polyclonal antibodies by providing consistent and reproducible binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If polyclonal antibodies are used to detect histone PTMs, then broad recognition of multiple epitopes is achieved, but reproducibility and consistency of data are compromised
Solution Approach 1:
The patent segments the antibody population into monoclonal antibodies with defined specificities for individual histone PTMs. Instead of using a heterogeneous mixture of polyclonal antibodies, the invention isolates and characterizes specific monoclonal antibodies (e.g., E42.8, E42.10, E42.20) that recognize distinct epitopes, thereby achieving reproducibility through uniformity while maintaining versatility through the availability of multiple specialized antibodies
Solution Approach 2:
The patent changes the key parameter of antibody homogeneity by transitioning from polyclonal (heterogeneous) to monoclonal (homogeneous) antibodies. This parameter change fundamentally improves reproducibility while the panel of different monoclonal antibodies targeting different PTMs maintains the ability to detect multiple modifications
2Measurement precision
If monoclonal antibodies with high specificity are developed, then measurement precision is improved, but manufacturing complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-characterizing and validating a panel of monoclonal antibodies against specific histone PTMs before their use in research. The antibodies are produced, purified, and their specificities are established in advance (e.g., E42.8 for H3K4me3, E42.10 for H3K4me2), creating a ready-to-use reagent panel that simplifies subsequent experimental work while maintaining high precision
Solution Approach 2:
The patent creates a universal panel of monoclonal antibodies that can be applied across multiple detection platforms and experimental workflows. The same set of characterized monoclonal antibodies serves diverse functions including Western blotting, chromatin immunoprecipitation, and immunofluorescence, thereby reducing the need for separate antibody development for each application
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These recombinant antibodies offer enhanced specificity and affinity, allowing for more reliable and reproducible data in studies of histone PTMs, facilitating improved research in chromatin biology and epigenetics, and enabling methods for cancer risk evaluation.
Implementation Method 1
recombinant antibodies that specifically recognize and bind histone post-translational modifications (PTMs)
Data Source
AI summary
Embodiments concern compositions and methods involving recombinant antibodies to histone post-translational modifications. The invention provides compositions and methods for histone methyltransferase assays. In certain embodiments, the compositions and methods involve a recombinant antibody that binds histone H3 fragment harboring biomarkers such as H3K9me3 mark, H3K4me3 mark, H3K36me3 mark, H3K27me3, H3K9me3 and H3S10phos or a recombinant antibody that binds histone H4 fragment harboring H4K20me3 mark.